Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium
- University Hospital Ghent
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient is 18 years or older.
- Signed Informed Consent.
- Subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered RAI refractory. There is evidence of persisting or recurrent disease, based on serum thyroglobulin levels and/or medical imaging.
- Subject should have a routine clinical 18F-FDG PET/CT performed within two months prior to the study scan.
- Female patients should be either post-menopausal, surgically sterile, or using highly effective contraceptives (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).
Exclusion Criteria:
- Patient has a known other active malignancy.
- Subject is potentially pregnant (urinary test can be performed in case of doubt) or breastfeeding.
- Patient is mentally or legally incapacitated.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Overal Trial
only one arm in this trial
|
PET/CT scan with F18-PSMA-11
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demonstrate uptake of 18F-PSMA-11 in RAI-RTC
Time Frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
|
Confirmation in PET-scan that lesions in RAI-RTC show uptake of 18F-PSMA-11, above background activity in the bloodpool.
|
60 minutes +- 5 minutes after injection 18F-PSMA-11
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Perform a semi-quantitative analysis of radiotracer uptake in lesions.
Time Frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
|
60 minutes +- 5 minutes after injection 18F-PSMA-11
|
|
Perform a lesion detection rate analysis on organ level.
Time Frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
|
60 minutes +- 5 minutes after injection 18F-PSMA-11
|
|
Compare uptake of 18F-PSMA-11 in these patients to the uptake of 18F-FDG, on a lesion basis.
Time Frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
|
60 minutes +- 5 minutes after injection 18F-PSMA-11
|
|
Evaluate the sufficiency of uptake of 18F-PSMA-11 to consider therapy with 177Lu-PSMA in a subset of patients
Time Frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
|
60 minutes +- 5 minutes after injection 18F-PSMA-11
|
|
Compare the histological expression of PSMA on already available tumor samples with the uptake of lesions on PSMA PET.
Time Frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
|
60 minutes +- 5 minutes after injection 18F-PSMA-11
|
|
Analyse the correlation between the serum level of PSMA and the uptake on PSMA PET
Time Frame: 60 minutes +- 5 minutes after injection 18F-PSMA-11
|
60 minutes +- 5 minutes after injection 18F-PSMA-11
|
|
Compare the histological expression of PSMA on already available tumor samples with the serum level of PSMA.
Time Frame: Within 1 year
|
Within 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BC-09501
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.